Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acurx Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ACXP
Nasdaq
2836
www.acurxpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acurx Pharmaceuticals, Inc.
New to The Street Show #781 Premieres Tonight on Bloomberg Television with Roadzen, Robo.ai, PureCipher and American Fusion
- Nov 21st, 2026 10:30 am
New to The Street Show #780 Premieres Tonight on Bloomberg Television with Robo.ai, American Fusion, Stewards Investment Capital and FreeCast
- Nov 14th, 2026 10:18 am
Acurx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
- Nov 12th, 2026 11:00 am
Acurx Pharma (ACXP) Q3 2026 Earnings Call Transcript
- Nov 12th, 2026 10:14 am
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
- Nov 12th, 2026 5:01 am
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
- Nov 7th, 2026 10:05 am
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
- Oct 31st, 2026 10:00 am
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
- Oct 26th, 2026 6:01 am
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
- Oct 24th, 2026 8:30 am
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
- Oct 21st, 2026 6:01 am
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
- Oct 5th, 2026 11:25 am
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
- Sep 29th, 2026 6:01 am
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
- Sep 19th, 2026 9:45 am
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
- Sep 14th, 2026 6:01 am
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
- Aug 20th, 2026 7:02 pm
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
- Aug 17th, 2026 6:01 am
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
- Aug 14th, 2026 10:56 am
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
- Aug 14th, 2026 5:01 am
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
- Aug 12th, 2026 6:01 am
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
- Aug 10th, 2026 6:01 am
Scroll